Monday, Oct. 5, was probably the first day of 2020 that SARS-CoV-2 had serious competition for science media attention – by another virus. The Nobel Assembly awarded the 2020 Nobel Prize for Physiology or Medicine to Harvey Alter, Michael Houghton and Charles Rice “for the discovery of hepatitis C virus.”
Anti-infective drugs approved over the last two decades were able to get through the clinical development and FDA approval processes substantially faster than other drugs, according to a new report from the Tufts Center for the Study of Drug Development.
Researchers at the University of Virginia have used a retrospective database analysis to show that the use of nucleoside reverse transcriptase inhibitors for the treatment of HIV or hepatitis B reduced the risk of developing type 2 diabetes by 33%.
PERTH, Australia – Sydney-based Recce Pharmaceuticals Ltd. completed a placement of AU$27.95 million (US$19.69 million) to advance its synthetic anti-infective pipeline to address antibiotic-resistant superbugs and emerging viral pathogens.
DUBLIN – Finch Therapeutics Inc. closed a $90 million series D round to take its oral microbiome therapy, CP-101, into late-stage clinical development and registration in chronic Clostridioides difficile infection and to move two additional programs, for chronic hepatitis B virus infection and autistic spectrum disorder, into the clinic.
DUBLIN – Adrenomed AG reported its anti-adrenomedullin antibody, adrecizumab, attained an absolute reduction of 9% in mortality as compared with placebo at both 14 and 28 days (D28) after treatment in a phase II trial in a large subgroup of patients with septic shock.
After a steady upward trend since the beginning of the year, the BioWorld Infectious Diseases index has hit a speed bump for the first time and dropped almost 8% so far in August. Companies in the group focusing on treatments for COVID-19 took the brunt of the valuation decline as investors became notably anxious about other drug developers making it to market sooner with their COVID-19 therapies.
HONG KONG Researchers from the Massachusetts Institute of Technology’s (MIT) research enterprise in Singapore, known as Singapore-MIT Alliance for Research and Technology (SMART), have found a way to not just reverse antibiotic resistance but also increase sensitivity in some bacteria, using hydrogen sulfide.
RSS
